'Survival benefit' presentation slideshows

Facing the Organ Shortage Crisis: Business as Usual vs Non-Conventional Solutions?

Facing the Organ Shortage Crisis: Business as Usual vs Non-Conventional Solutions?. Richard Perez MD Division of Transplant Surgery UC Davis Medical Center. Rationale for Transplantation. Survival benefit vs dialysis Improvement in quality of life Economic benefit to health care system.

721 views • 59 slides

Antiviral Drug Products Advisory Committee Meeting

766 views • 51 slides

Use of CRRT in ECMO: Is It Valuable?

1.84k views • 47 slides

Intubation in the Field CON

526 views • 41 slides

Molecular Profiling and Patient Selection

509 views • 25 slides

Radiation therapy for Early Stage Prostate Cancer

Radiation therapy for Early Stage Prostate Cancer. John A. Kalapurakal MD Professor, Radiation Oncology Northwestern University Medical School Chicago, IL . ARS. ? 1-B.

543 views • 24 slides

BACKGROUND

Sex Differences in Implantable Cardioverter Defibrillator (ICD) Implantation indications and outcomes.

334 views • 17 slides

1 O'Shaughnessy J et al. Proc ASCO 2010;Abstract 1005. 2 Brufsky A et al.

303 views • 17 slides

Clinton Memorial Hospital

482 views • 15 slides

Celebrating Life

297 views • 15 slides

About these Slides

About these Slides. Slide Use Guidelines. Effect of Pretransplant Serum Creatinine on the Survival Benefit of Liver Transplantation. Background. Methods. Results. Figure 1. Distribution of Serum Creatinine and Renal Replacement Therapy at LT Within Each MELD Category.

241 views • 14 slides

Xeloda: Improving survival in pancreatic cancer

291 views • 12 slides

250 views • 8 slides

Treatment 6 cycles of: Doxorubicin 60 mg/m 2 IV* Day 1 in 21-day cycles Sorafenib 400 mg po bid

Final Results From a Phase II, Randomized, Double-blind Study of Sorafenib Plus Doxorubicin Versus Placebo Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma. Authors: Abou-Alfa GK, Johnson P, Knox J, Davidenko I, Lacava J, Leung T, Mori A, Leberre M-A, Voliotis D, & Saltz LB

266 views • 8 slides

Thank you for downloading this update. Please feel free to use it for educational purposes.

ASCO 2010 Phase III Trial of Bevacizumab in the Primary Treatment of Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer: A Gynecologic Oncology Group (GOG) Study.

226 views • 7 slides

AF: Issues with Anticoagulation

AF: Issues with Anticoagulation. AFL: Anticoagulation like AF When undergoing procedures with risk for bleeding: May DC warfarin for up to one week without substituting heparin except for high risk pts. (Prosthetic valves, prior stroke or TIA). Class IIa (c)

216 views • 6 slides

LIFE PARTNER PLUS

LIFE PARTNER PLUS. Max life. Requirements. Minimum age: 35+ and 60 below. Monthly payments: R s.10,000 Time period of payment: 20 years Total investment: Rs.2,00,000. The Outcome. Age of return: starts from the age of 51 Monthly payments: Rs . 9278 Period of payment: 15 years.

209 views • 5 slides

Patients who received PORT were younger than patients who did not receive PORT.

Postoperative Radiotherapy for Patients with Stage II or III Nonsmall Cell Lung Cancer treated with Sublobar Resections: A SEER Registry Analysis

169 views • 4 slides

RESULTS

Comparative effectiveness of Partial versus Radical Nephrectomy in the treatment of patients with early-stage K idney C ancer Hung-Jui Tan MD 1 , Edward C. Norton PhD 2 , Zaojun Ye MS 1 , Khaled S. Hafez MD 1 , John L. Gore MD, MS 3 , and David C. Miller MD, MPH 1,2

120 views • 1 slides

Table 1 Phase III trials with a survival benefit in metastatic CRPC

Table 1 Phase III trials with a survival benefit in metastatic CRPC. Sartor, O. & Pal, S. K. ( 2012) Abiraterone and its place in the treatment of metastatic CRPC Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2012.202.

120 views • 1 slides